Hycamtin Capsules

  • Respiratory and thoracic cancers

Hycamtin Capsules Generic Name & Formulations

General Description

Topotecan (as HCl) 0.25mg, 1mg; caps.

Pharmacological Class

Topoisomerase inhibitor.

See Also

How Supplied

Single-use vials—1; Caps—10

Hycamtin Capsules Indications


Relapsed small cell lung cancer with prior complete or partial response and at least 45 days from the end of 1st line chemotherapy.

Hycamtin Capsules Dosage and Administration


Confirm baseline neutrophils ≥1,500cells/mm3 and platelets ≥100,000cells/mm3 prior to 1st course of therapy. Swallow whole. 2.3mg/m2/day once daily for 5 consecutive days, starting on Day 1 of a 21-day cycle. Renal impairment (CrCl 30–49mL/min): 1.5mg/m2/day; (CrCl <30mL/min): 0.6mg/m2/day. Dose modifications: see full labeling.


Not established.

Hycamtin Capsules Contraindications

Not Applicable

Hycamtin Capsules Boxed Warnings

Boxed Warning


Hycamtin Capsules Warnings/Precautions


Monitor blood counts frequently during therapy; hold subsequent doses until neutrophils >1,000cells/mm3, platelets >100,000cells/mm3, and hemoglobin ≥9g/dL. History of interstitial lung disease (ILD), pulmonary fibrosis, lung cancer, thoracic radiation, use of pneumotoxic drugs and/or colony stimulating factors. Monitor for pulmonary symptoms indicative of ILD; permanently discontinue if ILD is confirmed. Moderate to severe renal impairment (see Adults). Caps: severe diarrhea; may need to reduce dose. IV: avoid extravasation. Embryo-fetal toxicity. Advise use of effective contraception during and for 6 months (females) or 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Hycamtin Capsules Pharmacokinetics

See Literature

Hycamtin Capsules Interactions


IV: myelosuppression potentiated with platinum agents. Caps: potentiated by P-gp (eg, cyclosporine) or BCRP inhibitors; avoid concomitant use.

Hycamtin Capsules Adverse Reactions

Adverse Reactions

Neutropenia, anemia, thrombocytopenia, febrile neutropenia, nausea, vomiting, fatigue, diarrhea, dyspnea, asthenia, pneumonia, abdominal pain, pain, infection, alopecia, anorexia; ILD, neutropenic colitis (may be fatal).

Hycamtin Capsules Clinical Trials

See Literature

Hycamtin Capsules Note

Not Applicable

Hycamtin Capsules Patient Counseling

See Literature